Safety and efficacy of panitumumab following cetuximab: Retrospective review of the Memorial Sloan-Kettering experience Journal Article

  

Authors:	Power, D. G.; Shah, M. A.; Asmis, T. R.; Garcia, J. J.; Kemeny, N. E.
Article Title:	Safety and efficacy of panitumumab following cetuximab: Retrospective review of the Memorial Sloan-Kettering experience
Abstract:	There are two highly selective antibodies to the epidermal growth factor receptor (EGFR) now available for use in metastatic colorectal cancer (mCRC). In KRAS wild type patients, cetuximab (Cmab)-an IgG1 chimeric molecule-has activity alone and in combination with chemotherapy for the first, second and third-line settings. Panitumumab (Pmab)-a fully humanized IgG2 molecule-has activity as a single agent in chemorefractory mCRC and shows promising activity in combination with chemotherapy. It remains unclear which antibody to use. This retrospective review of our experience with Pmab in 13 EGFR antibody-naive patients and in 22 patients previously treated with Cmab for mCRC highlights a lack of hypersensitivity reactions (HSR) with Pmab, even in patients who experienced HSR to Cmab. In patients who received Cmab, 22% developed grade 3-4 HSR. There were no HSR on subsequent treatment with Pmab. We demonstrate similar activity in 95% of cases, between Cmab and Pmab both alone and in combination with chemotherapy in the treatment of mCRC. In one case we report unique sensitivity to Pmab after progression with Cmab. © 2009 Springer Science+Business Media, LLC.
Keywords:	adult; aged; middle aged; retrospective studies; drug tolerability; review; bevacizumab; fluorouracil; cancer combination chemotherapy; diarrhea; drug efficacy; drug safety; drug withdrawal; monotherapy; side effect; skin toxicity; colorectal cancer; drug eruption; antineoplastic combined chemotherapy protocols; retrospective study; cetuximab; irinotecan; panitumumab; chill; drug hypersensitivity; flushing; hypomagnesemia; loading drug dose; pruritus; hypoxia; colorectal neoplasms; hypotension; antibodies, monoclonal; drug response; acne; neoplasm metastasis; drug infusion; nail; metastasis potential; drug substitution; oxaliplatin; floxuridine; anaphylaxis; urticaria; face disorder; metastatic colorectal cancer; swelling; hypersensitivity reactions; lip disease
Journal Title:	Investigational New Drugs
Volume:	28
Issue:	3
ISSN:	0167-6997
Publisher:	Springer
Date Published:	2010-06-01
Start Page:	353
End Page:	360
Language:	English
DOI:	10.1007/s10637-009-9268-y
PUBMED:	19468688
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-77952239903&partnerID=40&md5=9f0cc8ebd9d0dbaed90737a20fc6aea6
Notes:	--- - "Cited By (since 1996): 3" - "Export Date: 20 April 2011" - "CODEN: INNDD" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/4876